MAGNA Stock Overview
A diagnostic company, develops and commercializes tests for monitoring and optimizing the dosage of biological drugs Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Magnasense AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.17 |
| 52 Week High | SEK 1.50 |
| 52 Week Low | SEK 0.16 |
| Beta | 2.63 |
| 11 Month Change | -33.20% |
| 3 Month Change | -52.29% |
| 1 Year Change | -81.54% |
| 33 Year Change | -99.69% |
| 5 Year Change | n/a |
| Change since IPO | -98.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAGNA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -13.8% | 3.3% | 1.0% |
| 1Y | -81.5% | 35.0% | 25.9% |
Return vs Industry: MAGNA underperformed the Swedish Biotechs industry which returned 35% over the past year.
Return vs Market: MAGNA underperformed the Swedish Market which returned 25.9% over the past year.
Price Volatility
| MAGNA volatility | |
|---|---|
| MAGNA Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.0% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: MAGNA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: MAGNA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 14 | Marco Wititteveen | www.magnasense.com |
Magnasense AB, a diagnostic company, develops and commercializes tests for monitoring and optimizing the dosage of biological drugs Sweden and internationally. The company focuses on the neurology, oncology, and autoimmune therapeutic areas. It offers moNATor, a first dose-monitoring laboratory test that provides multiple sclerosis for healthcare professionals and patients; and Viraspec, a COVID-19 saliva test kit.
Magnasense AB Fundamentals Summary
| MAGNA fundamental statistics | |
|---|---|
| Market cap | SEK 8.22m |
| Earnings (TTM) | -SEK 41.42m |
| Revenue (TTM) | SEK 35.00k |
235.0x
P/S Ratio-0.2x
P/E RatioIs MAGNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAGNA income statement (TTM) | |
|---|---|
| Revenue | SEK 35.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 35.00k |
| Other Expenses | SEK 41.45m |
| Earnings | -SEK 41.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | -118,334.29% |
| Debt/Equity Ratio | -305.1% |
How did MAGNA perform over the long term?
See historical performance and comparison